Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)5.18
  • Today's Change-0.01 / -0.19%
  • Shares traded16.70m
  • 1 Year change-24.38%
  • Beta0.6349
Data delayed at least 15 minutes, as of Nov 22 2024 03:34 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CSPC Pharmaceutical Group Ltd is an investment holding company primarily engaged in the manufacture and sale of pharmaceutical products. The Company operates its business through three segments. The Finished Drugs segment in engaged in the research and development, manufacture and sale of pharmaceutical products and licensing business. The Bulk Products segment is engaged in the manufacture and sale of vitamin C, and antibiotic products in bulk powder form. The Functional Food and Others segment is engaged in the manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. The Company’s product therapeutic areas include nervous system, oncology, anti-infectives, cardiovascular, respiratory system, digestion and metabolism and others. The Company conducts its business in the domestic and overseas markets.

  • Revenue in HKD (TTM)32.55bn
  • Net income in HKD5.54bn
  • Incorporated1992
  • Employees20.30k
  • Location
    CSPC Pharmaceutical Group LtdNo. 226 Huanghe StreetSHIJIAZHUANG 050035ChinaCHN
  • Phone+86 31 187037015
  • Fax+86 31 187039608
  • Websitehttps://www.cspc.com.hk/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
WuXi XDC Cayman Inc3.01bn639.28m31.67bn1.50k50.274.9143.5010.530.52520.52522.665.380.558621.312.852,551,697.0011.88--15.43--30.96--21.27--4.02--0.0113--114.44--82.07------
China Resources Pharmaceutical Group Ltd269.40bn4.06bn34.11bn72.76k8.400.6562.740.12660.64610.646142.888.280.9666.093.283,691,123.003.193.0212.1311.3515.7815.723.312.871.1211.500.439624.7312.168.8610.112.8013.587.05
CSPC Pharmaceutical Group Ltd32.55bn5.54bn60.94bn20.30k11.11--32.711.870.46890.46892.76--------1,385,050.00--16.08--21.5770.5972.9517.2819.63--25.15--35.511.6612.16-3.5813.77-2.5825.33
Sino Biopharmaceutical Ltd28.81bn2.15bn63.51bn24.44k28.991.7510.212.200.11660.23861.561.930.40502.373.741,116,518.007.4213.1114.5021.7482.9280.3718.3327.471.0718.130.186825.020.66574.63-10.29-27.22-7.181.15
Innovent Biologics Inc8.02bn-1.38bn63.55bn5.26k--4.73--7.93-0.8635-0.86355.008.210.39051.326.251,645,701.00-6.71-13.06-8.22-15.8582.4484.51-17.18-43.442.51-6.910.2123--36.21265.7952.83--34.60--
Data as of Nov 22 2024. Currency figures normalised to CSPC Pharmaceutical Group Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

13.95%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 06 Nov 2024320.14m2.74%
First Sentier Investors (Hong Kong) Ltd.as of 31 Jul 2024273.57m2.34%
Norges Bank Investment Managementas of 30 Jun 2024233.11m1.99%
UBS Asset Management Switzerland AGas of 06 Nov 2024176.24m1.51%
BlackRock Fund Advisorsas of 23 Sep 2024139.21m1.19%
Hang Seng Investment Management Ltd.as of 08 Nov 2024128.11m1.10%
UBS Asset Management (Hong Kong) Ltd.as of 06 Nov 2024100.26m0.86%
Dimensional Fund Advisors LPas of 07 Nov 202494.19m0.81%
BlackRock Advisors (UK) Ltd.as of 23 Sep 202485.62m0.73%
GF Fund Management Co., Ltd.as of 30 Jun 202481.03m0.69%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.